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A B S T R A C T
Purpose
To compare the local recurrence (LR) rate between short-course (SC) and long-course (LC)
neoadjuvant radiotherapy for rectal cancer.
Patients and Methods
Eligible patients had ultrasound- or magnetic resonance imaging–staged T3N0-2M0 rectal adeno-
carcinoma within 12 cm from anal verge. SC consisted of pelvic radiotherapy 5  5 Gy in 1 week,
early surgery, and six courses of adjuvant chemotherapy. LC was 50.4 Gy, 1.8 Gy/fraction, in 5.5
weeks, with continuous infusional fluorouracil 225 mg/m2 per day, surgery in 4 to 6 weeks, and
four courses of chemotherapy.
Results
Three hundred twenty-six patients were randomly assigned; 163 patients to SC and 163 to LC.
Median potential follow-up time was 5.9 years (range, 3.0 to 7.8 years). Three-year LR rates
(cumulative incidence) were 7.5% for SC and 4.4% for LC (difference, 3.1%; 95% CI, 2.1 to 8.3;
P  .24). For distal tumors ( 5 cm), six of 48 SC patients and one of 31 LC patients experienced
local recurrence (P  .21). Five-year distant recurrence rates were 27% for SC and 30% for LC
(log-rank P  0.92; hazard ratio [HR] for LC:SC, 1.04; 95% CI, 0.69 to 1.56). Overall survival rates
at 5 years were 74% for SC and 70% for LC (log-rank P  0.62; HR, 1.12; 95% CI, 0.76 to 1.67).
Late toxicity rates were not substantially different (Radiation Therapy Oncology Group/European
Organisation for Research and Treatment of Cancer G3-4: SC, 5.8%; LC, 8.2%; P  .53).
Conclusion
Three-year LR rates between SC and LC were not statistically significantly different; the CI for the
difference is consistent with either no clinically important difference or differences in favor of LC.
LC may be more effective in reducing LR for distal tumors. No differences in rates of distant
recurrence, relapse-free survival, overall survival, or late toxicity were detected.
J Clin Oncol 30:3827-3833. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Adding radiotherapy to surgery has been shown
conclusively to improve local control for rectal can-
cer.1,2 Short-course preoperative radiotherapy of 25
Gy in 5 consecutive days has been shown to be effec-
tive in tumor control. The Swedish Rectal Cancer
Trial3 demonstrated that short-course preoperative
radiotherapy reduced the risk of local recurrence
(LR) by half. In this study, improvedoverall survival
was also evident. The Dutch Rectal Cancer Trial4
demonstrated that short-course preoperative radio-
therapy maintains its benefit when combined with
thebest surgical practice—totalmesorectal excision.
It was through meticulous study design and qual-
ity assurance that the value of short-course preop-
erative radiotherapy in addition to surgery was
put beyond doubt. The MRC (Medical Research
Council) CR07 rectal trial,5 which compared short-
course preoperative radiotherapy with selective post-
operative chemoradiotherapy, provided further
support for the short course approach.
Long-course preoperative chemoradiotherapy
of 50.4 Gy in 5 weeks and 3 days with concurrent
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chemotherapy has been widely practiced in the last 15 years. This
regimen’s superiority, in terms of local control, was demonstrated in
the German rectal cancer trial,6when compared with postoperative
chemoradiotherapy. The use of long-course preoperative chemora-
diotherapy with different chemotherapeutic and biologic agents has
been investigated with the aim of further improving local control
and survival.7,8
Althoughbothshort-coursepreoperative radiotherapyand long-
course preoperative chemoradiotherapy have been practiced in paral-
lel for more than 15 years, it has not been clear which form of
preoperative radiotherapy provides better tumor control. We per-
formed a randomized trial for clinical stage T3 rectal cancer compar-
ing short-course radiotherapy with long-course chemoradiotherapy.
In this article,we report our results after aminimumfollow-upperiod
of 3 years, and we include the comparison of LR rates, relapse-free
survival, overall survival, and late toxicity.
This trialwasperformedunder theauspicesof theTrans-Tasman
Radiation Oncology Group, Australasian Gastro-Intestinal Trials
Group,Colorectal Surgical Society ofAustralia andNewZealand, and
The Royal Australasian College of Surgeons.
PATIENTS AND METHODS
The protocol was approved by the ethics committees of all participating cen-
ters. Written informed consent was obtained from each patient.
Patients
Eligible patients were those with histologically confirmed rectal adeno-
carcinoma, with lower borders within 12 cm of the anal verge; ultrasound- or
magnetic resonance imaging (MRI) –staged T3 disease; Eastern Cooperative
Oncology Group (ECOG) performance status 0 to 2; neutrophil count
 1.5 109/L; platelet count 100 109/L; bilirubin and ALT 1.5 times
the upper limit of normal; and serumcreatinine 1.5 times the upper limit of
normal. Exclusion criteria included evidence of distant metastases, recurrent
rectal cancer, unstable cardiac disease, active infection, other cancers within 5
years, and prior radiotherapy. There was no restriction on nodal stage.
Study Design and Treatments
Eligible patients were randomly assigned to receive either short-course
radiotherapy (SC) or long-course chemoradiotherapy (LC). SC comprised
radiotherapy alone with a total of 25 Gy in five fractions administered in 1
week, followedby surgery 3 to 7 days later. Sixmonthly courses of fluorouracil
(FU; 425 mg/m2) and folinic acid (20 mg/m2) administered daily for 5 days
commenced 4 to 6 weeks after surgery.
LC chemoradiotherapy comprised a total of 50.4 Gy in 28 fractions over
5 weeks and 3 days with continuous infusional FU 225 mg/m2 per day,
administered 7 days perweek for the duration of radiation. Surgery followed 4
to 6weeks after chemoradiotherapy. Fourmonthly courses of the same chem-
otherapy as for SC patients commenced 4 to 6 weeks postsurgery.
The radiation clinical target volume (CTV) for SC was to include the
primary rectal cancer, perirectal and internal iliac nodes, mesorectum, pelvic
sidewalls, andpresacral spacewith theupper border at the sacral promontory.
The CTV for the initial phase of LCwas identical to that for SC. The CTVwas
reduced after a total of 45 Gy to include gross disease with a 2-cm margin.
Pelvic radiotherapy was administered using three- or four-field techniques.
Treatment planning was performed with computerized dosimetry. Verifica-
tion images were performed weekly.
Surgerywas tobeperformedaccording to theAustralianNationalHealth
andMedical Research Council guidelines.9 Central pathology review was not
a requirement.
Assessments
Before randomassignment, patient assessment included sigmoidoscopy
andbiopsy, colonoscopy, computed tomography(CT)of theabdomen/pelvis,
chest x-ray or CT, endorectal ultrasound or pelvic MRI, full blood examina-
tion, renal and liver function tests, carcinoembryonic antigen (CEA), and
International Normalized Ratio. Enlarged nodes on staging were noted but
nodal status was not an eligibility criterion.
Following completion of the protocol therapy, patient status was re-
viewed every 3months for 24months, then once every 6months until 5 years
postsurgery, then once a year thereafter. Liver function and CEA tests were
performed at each visit. Late toxicity was assessed every 6 months for 24
months, then yearly until 5 years postsurgery, and was graded using the
RadiationTherapyOncologyGroup/EuropeanOrganisation forResearchand
Treatment of Cancer Late RadiationMorbidity Scoring Scheme.10
End Points
LR was defined as recurrence within the true pelvis and either con-
firmed histologically or diagnosed from one or more of the following:
progressive radiographic (CT orMRI) changes in a pelvic soft-tissue mass;
progressive pelvic painwith radiographic changes; abnormally high uptake
in the true pelvis on positron emission tomography scan; and visible or
palpable tumor in the presence of distant metastasis. An independent
review panel reviewed all recorded cases of LR. Recurrence outside the true
pelvis was defined as distant.
Times to events were measured from random assignment or operation,
as appropriate, and censored at the close-out date for analysis. The LR rate at a
given time was defined as the cumulative incidence of LR (competing risks
analysis with death as the other competing event). A similar definition applied
to the distant-recurrence rate. Analysis of the competing risks of site of first
recurrence and death was performed. Recurrence-free survival (RFS) was
defined as time to recurrence or death, and overall survival (OS) as time to
Allocated to LC RT arm
      Received LC RT and chemo
      Received LC RT, no chemo
      Did not receive RT
(n = 163)
(n = 159)
(n = 1)
(n = 3)
Allocated to SC RT arm
   Received SC RT
   Received LC RT
   Did not receive RT
(n = 163)
(n = 159)
(n = 2)
(n = 2)
Withdrew consent; no treatment;
   no follow-up data
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   no follow-up data
(n = 2)
Randomly assigned
(N = 326)
Analyzed
   ITT patients analyzed
(n = 162)
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   ITT patients analyzed
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(n = 161)
Fig 1. CONSORT diagram. Chemo, chem-
otherapy; ITT, intention-to-treat; LC, long
course; RT, radiotherapy; SC, short course.
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death fromany cause.A closeout datewas set atMay22, 2009, 3 years from the
end of accrual. All data arising after this date were ignored to minimize
reporting bias.
Statistical Analysis
The trial was designed to have 80% power to detect a difference in the
primary end point, the LR rate at 3 years, of 15% (SC) versus 5% (LC)11,12
using a two-sided test at the 5% level of significance. Three hundred ten
evaluable patients, with a minimum follow-up of 3 years, were required.
Patients were randomly assigned to study arms in a 1:1 ratio using an adaptive
biased coin technique within strata corresponding to radiotherapy center. No
specific early stopping rules were employed; in particular, there were no in-
terim efficacy analyses, but there was ongoing monitoring of safety, data
quality, protocol compliance, and accrual rate, including review by an Inde-
pendent Data Monitoring Committee on four occasions during the ac-
crual period.
LR rates were compared using their SEs as computed from the compet-
ing risks method and assuming approximate normality. The primary analysis
was unadjusted and based on the intention-to-treat principle, namely that all
eligible and evaluable patients were included in the analysis and analyzed
according to thearmtowhich theywereassigned.Subsidiaryanalyses included
Gray’s test for comparing cumulative incidence curves and analyses adjusting
for prognostic variables.
Secondary aims compared treatmentswith respect to time toLR, time to
distant recurrence, RFS, and OS via log-rank and Cox regression methods.
Log-rank tests were exact, being based on hypergeometric probabilities. RFS
andOS curves were estimated using the Kaplan-Meiermethod. P values from
contingency tables were exact. Analyses of prognostic factors including sex,
age, ECOG performance status (0 v 1-2), node positivity, distance from anal
verge (continuous), (log) CEA, and treatment arm, withmultiple imputation
of missing values13 for node status and CEA; also margin positivity (macro-
scopic or microscopic), ypT, and ypN were included in analysis at operation,
and were performed using backward elimination. Late toxicity rates (crude)
were tabulated by type and compared by arm. Important end points were
calculated using 95% CIs and P values were two-sided. Analyses were per-
formed using the R statistical language (http://www.R-project.org).
RESULTS
Twenty-seven centers in Australia and New Zealand contributed
patients from 2001 to 2006; 326 patients were randomly assigned,
163 to each arm (Fig 1). Three patients withdrew completely from
the trial before treatment and were excluded, leaving 323 patients
for analysis (SC, 162; LC, 161). The median potential follow-up
time was 5.9 years and, for patients not lost to follow-up, ranged
from3.0 to 7.8 years. Eleven patients (SC, 6; LC, 5)with incomplete
follow-up had a median follow-up time of 3.5 years (range, 0.9 to
6.0). Table 1 lists distributions of patient characteristics between
study arms. These seem well-balanced except for distance from
anal verge, which tends to be shorter in SC patients (30% 5 cm
compared with 19% of LC patients).
All patients administered SC received a total of 25Gy; of patients
administered LC, 93% received a total of 50.4Gy, and 84%of patients
received concurrent FU within 10% of the planned dose. Adjuvant
chemotherapy was delivered to 85% of SC and 86% of LC patients.
Reasons for not receiving adjuvant chemotherapy were health-
related issues (61% of patients), patient decision (24%), and clini-
cian decision (15%).
Local Recurrence
Twenty-one patients experienced LR as a first or subsequent
recurrence (SC, 12; LC, 9), and 79 died without prior LR (SC, 35; LC,
44). Cumulative incidences of LR at 3 years were 7.5% for SC (SE,
2.1%)and4.4%forLC(SE, 1.6%;difference, 3.1%;95%CI,2.1%to
8.3%; P 0.24). Cumulative incidence curves of LRwere not statisti-
cally different (Gray’s test P .49; Fig 2A). Cumulative incidences of
LR at 5 years were 7.5% for SC (SE, 2.1%) and 5.7% for LC (SE, 1.8%;
difference, 1.8%; 95%CI,3.6% to 7.3%; P 0.51).
The observed risk of LR (log-rank analysis) was smaller for LC
but not statistically significant (HR for LC:SC, 0.75; 95% CI, 0.32 to
1.77; P .66). Thirteen patients experienced LR as a first recurrence;
the observed risk was less for LC but not statistically significantly so
(HR for LC:SC, 0.64; 95%CI, 0.22 to 1.89; P .58).
Prognostic Factors at Baseline for Local Recurrence
Age, ECOG performance status, node positivity, and CEA
were significant determinants of LR in univariable analyses. In
multivariable analysis of the seven factors considered (see Statisti-
cal Analysis), only CEA was statistically significant (HR, 1.43; per
doubling, P .001).
Table 1. Patient Characteristics by Arm
Characteristic
SC (n  162) LC (n  161)
No. of
Patients %
No. of
Patients %
Sex
Male 117 72 120 75
Female 45 28 41 25
Age at random assignment, years
Median 63 64
Range 26 to 80 29 to 82
ECOG performance status
0 102 63 87 54
1 59 36 71 44
2 1 1 3 2
T3 stage 162 100 161 100
N stage
0 91 56 90 56
1 59 36 59 37
2 1 1 2 1
X 11 7 10 6
M0 stage 162 100 161 100
CEA, ng/ml
Median 3.0 3.0
Range 0.2 to 375 0.10 to 304
Missing 16 8
Staging investigations
MRI staged 49 30 51 32
Ultrasound staged 84 52 81 50
MRI plus ultrasound 20 12 17 11
CT staged 9 6 12 7
Distance of lower border from
anal verge, cm
0 to  5 48 30 31 19
 5 to  10 88 54 88 55
 10 to 12 26 16 42 26
Mean 6.2 7.0
Range 0 to 12 0 to 12
Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography;
ECOG, Eastern Cooperative Oncology Group; LC, long course; MRI, magnetic
resonance imaging; SC, short course.
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Relapse and Survival
Sites of first relapse by arm are listed in Table 2. Figure 2B shows
cumulative incidence curves by site of first recurrence (local and/or
distant) and death without recurrence and by treatment arm.
Ninety-three patients (SC, 46; LC, 47) experienced a distant
recurrence either as a first or subsequent recurrence. Five-year cumu-
lative incidence rates of distant recurrence were 27% and 30% for SC
and LC, respectively (Gray’s test P  .89). There were no apparent
differences in relative risksofdistant recurrence (log-rankP .92;HR
for LC:SC, 1.04; 95%CI, 0.69 to 1.56).
Relapse or death was experienced by 121 patients (SC, 57; LC,
64),withnodifference inRFSbetweenarms(HRforLC:SC,1.15; 95%
CI,0.80 to1.62;P .47;Figure3A).Ninety-ninepatientsdied(SC,47;
LC, 52), including21patients of causesunrelated to rectal canceror its
treatment.Therewasnodifferencedemonstrated inOSbetweenarms
(5-yearOS rates: SC, 74%;LC, 70%;HR for LC:SC, 1.12; 95%CI, 0.76
to 1.67; P .62; Figure 3B).
Operative Findings
Fiveof the323patientsdidnot receive theallocated treatment (ie,
SC or LC plus preoperative chemotherapy) and three patients did not
proceed to surgery. Operative findings of the remaining 315 patients
(SC, 158; LC, 157) are summarized in Table 3. The table of surgical
complications is summarized in Appendix Table A1 (online only).
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Fig 2. (A) Cumulative incidence curves of any local recurrence (LRec) by
allocated treatment arm: competing risks analysis for events, LRec, and death
(not shown). (B) Cumulative incidence curves of first relapse site (local—with or
without simultaneous distant—or distant alone) and death by allocated treatment
arm: competing risks analysis for events, local recurrence with or without
simultaneous distant recurrence (LRec  DRec), distant recurrence (DRec) only,
and death. LC, long course; SC, short course.
Table 2. First Relapse Site Combinations by Arm
Sites of First Recurrence SC LC Total
Local only 4 4 8
Distant only 38 44 82
Local and distant 4 1 5
Death without prior recurrence 11 15 26
Total No. of patients with recurrence 46 49 95
Total No. of patients who recurred or died 57 64 121
No recurrence or death 105 97 202
Total 162 161 323
Abbreviations: SC, short course; LC, long course.
HR (LC:SC) = 1.15; P = .47
HR 95% CI
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Fig 3. (A) Recurrence-free survival curves by allocated treatment arm. (B)
Overall survival curves by allocated treatment arm. HR, hazard ratio; LC, long
course; SC, short course.
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Pathologicdownstagingwassignificantlymorecommoninpatients
randomly assigned to LC (45% v 28%; P .002). In particular, 24 LC
patients (15%) had a pathologic complete response (ypT0) compared
with two SC patients (1%). In patients with distal tumors ( 5 cm), the
abdominoperinealresection(APR)rateswere79%(38of48patients)and
77%(23of 30 patients) for SC andLC, respectively (P .87).
Prognostic Factors at Operation for Local Recurrence
Patients withmajor eligibility infringements (two patients), ma-
jor protocol violations (five patients), no operation (three patients),
and distant metastasis detected before or at operation (11 patients)
were excluded, leaving 302 patients for analysis (SC, 153; LC, 149).
Patients analyzed include eight with macroscopically incompletely
resected tumors and eightwhose resected tumors had apositive resec-
tionmargin. Inmultivariable analysis, of the10 factors considered(see
Statistical Considerations) margin positivity (macro- ormicroscopic;
HR, 6.46;P .001), ypNpositivity (HR, 3.56;P .001), and baseline
CEA(HR, 1.32; per doubling,P .033)were independently prognos-
tic. For patients on LC, none of 20 pathologic complete response
(pCR) patients recurred locally compared with nine of 129 non-pCR
patients (P .38).
Distance From Anal Verge
When the whole cohort of 323 patients was analyzed, distance
from anal verge was not significantly related to risk of LR either as a
continuous covariate (univariate P .25; adjusting for arm P .29)
or comparing distal ( 5 cm) and proximal tumors (seven of 79 v 14
of 244, respectively;HR for distal:proximal, 1.59; 95%CI, 0.58 to 4.34;
log-rank P 0.31). There was no statistical evidence for a differential
effect of treatment on risk of LR according to distance fromanal verge
(interaction P 0.24).
For 79distal tumors therewas a large, observed (but not statistically
significant)differencebetween treatmentswith respect to riskofLR,with
six of 48 patients on SC and one of 31 patients on LC experiencing local
recurrence (HR for LC:SC, 0.26; 95% CI, 0.06 to 1.20; P  .26). The
cumulative incidences of local recurrence were 12.5% for SC (SE, 4.8%)
and0.0%forLC(SE,0.0).Acomparisonofthecrudeproportions(SC,six
of 48; LC, one of 31) gave P  .21. Of the 302 patients defined in the
Prognostic Factors at Operation for Local Recurrence section, similar
resultswereobtained fromanalysesofdata from103patientswhohadan
APRand58of these 103 patientswhohaddistal tumors.
Late Toxicity
RadiationTherapyOncologyGroup/EuropeanOrganisation for
Research andTreatmentofCancer late radiation toxicities are listed in
Table 4. The rates forG3-4, small or large intestine toxicity for SC and
Table 3. Operative Findings by Arm
Factor
SC LC
P
No. of
Patients %
No. of
Patients %
Distance of lower border
from anal verge at
baseline, cm .017
0 to  5 48 30 30 19
 5 to  10 86 54 87 55
 10 to 12 24 15 40 25
Macroscopic resection
Complete 154 97 153 97
Incomplete 4 3 4 3
Margin status†
Negative 150 95 151 96
Positive 8 5 6 4
ypT  .001‡
0 2 1 24 15
1 7 4 4 3
2 35 22 43 27
3 106 67 82 52
4 8 5 4 3
T downstaging .003§
Downstaged, ypT0-2 44 28 71 45 .002¶
Unchanged, ypT3 106 67 82 52
Upstaged, ypT4 8 5 4 3
ypN .50*
0 95 60 102 65
1 39 25 40 25
2 24 15 15 10
Grade, resection specimen .056
WD 3 2 7 6
MWD 100 66 93 74
PD/UD 28 18 18 14
Mixed 21 14 8 6
Unknown 4 8
N/A (CR) 2 23
Type of operation .22
APR 59 37 48 31
non-APR 99 63 109 69
NOTE. For 315 patients who received the allocated preoperative treatment
and proceeded to surgery. Data include 13 patients with major eligibility
infringements (n  2) or who had distant metastasis detected before or at
operation (n  11).
Abbreviations: APR, abdominoperineal resection; LC, long course; MWD, moder-
ately well differentiated; N/A (CR), not applicable (complete response); PD, poorly
differentiated; SC, short course; UD, undifferentiated; WD, well differentiated.
*df  2.
†Twelve circumferential and two distal.
‡df  4.
§P for trend; df  2.
¶P for T0-2 v T3-4.
df  3.
Table 4. Late RT Toxicities by Worst Grade
Late RT Toxicity Type
SC (n  155) LC (n  158)
Grade 3 Grade 4 Grade 3 Grade 4
Skin, pelvic 0 1 0 1
Subcutaneous tissue 0 1 0 1
Small or large intestine 2 3 6 2
Bladder 3 0 2 0
Other 2 1 3 0
Any toxicity 6 3 10 3
NOTE. The maximum grade (RTOG/EORTC Late Radiation Morbidity Scoring
Scheme) for each type and each patient was determined. Only grades 3 or 4
late toxicities are tabulated. Of the total number of patients evaluable for late
RT toxicity analysis, 155 patients received SC and 158 patients received LC.
Abbreviations: EORTC, European Organisation for Research and Treatment
of Cancer; LC, long course; RT, radiotherapy; RTOG, Radiation Therapy
Oncology Group; SC, short course.
Other reported toxicities for SC included vesicocutaneous fistula (grade 4),
anastomotic stricture requiring dilatations (grade 3), and proctalgia (grade 3).
Other toxicities for LC included deep venous thrombosis (grade 3), perianal
pain (grade 3), and presacral abscess (grade 3). The crude rates of late RT
toxicity were 5.8% (nine of 155 patients) for SC and 8.2% (13 of 158 patients)
for LC (P  .53).
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LC were 3.2% and 5.1%, respectively (difference for LC-SC, 1.8%;
95%CI,3.0% to 6.9%; P .53). The crude rates of any late grade 3
to 4RT toxicitywere 5.8% for SC (nine of 155) and8.2% for LC (13of
158; difference for LC-SC, 2.4%; 95% CI,3.6% to 8.5%; P .53)
and were not substantially different between arms.
DISCUSSION
This trial included only ultrasound- orMRI-staged, advanced can-
cers (cT3) and those with the lower edge of tumor in the lower
two-thirds of the rectum. In 6.5% of patients, CT evidence of
perirectal fat infiltration was accepted after unsuccessful endorec-
tal ultrasound (so that bulky or stenotic T3 lesions were not ex-
cluded). For the short-course arm of the Dutch trial14 stage I, II,
and III disease was included and adjuvant chemotherapy was not
used; our trial included only clinical T3 disease and adjuvant
chemotherapy was standardized in the protocol. The Polish trial15
differed from ours in that concurrent chemotherapy administered
during chemoradiotherapy was bolus FU and leucovorin, adjuvant
chemotherapy was optional, endorectal ultrasound or MRI was
not performed for all patients but was reserved for mobile lesions,
and all circular or tethered lesions on digital rectal examination
were determined as T3 or T4 tumors.
We demonstrated a small difference in the LR rate at 3 years, 3.1%,
favoring LC (P .24). The 95% CI for the difference (SC-LC: 95% CI,
2.1% to 8.3%) includes differences of 8% or more in favor of LC (eg,
10% v2%) so the trial hasnot excluded therebeing a clinically important
difference in3-yearLRrates.Thedataareconsistentwitheithernodiffer-
ence or an important clinical difference in favor of LC; it’s unlikely that
thereisanimportantdifferencefavoringSC.InthePolishtrial,16 therewas
nostatistically significantdifference inLRratebetweenSCandLCpreop-
erative radiotherapy, although the trend favored SC (4-year LR rates: SC,
10.6%; LC, 15.6%; P .21; inferred 95% CI for SC-LC approximately
11.3% to 1.3%). Results in the two trials are consistent with no true
difference in LR rates, althoughdifferences between arms are in opposite
directions. However, because of the trials’ different stage profiles it is
difficult tomake a valid comparison.
We did not find a statistically significant difference in LR risk
between treatments for distal cancer ( 5 cm), despite there being
a large observed difference favoring LC (six of 48 SC patients v one
of 31 LC patients recurred locally). This trend is consistent with the
common belief that LC is superior for distal T3 disease. It is also
consistentwithDutch trial results inwhich SC for distal diseasewas
relatively ineffective.14
Aspects of treatment other than radiotherapy in our trial, such as
the intensity of chemotherapy, were well balanced between the arms.
As therewasno significant difference inLRbetween study arms, itwas
not surprising that there were no significant differences in RFS orOS.
After surgery, positive resection margin, involved lymph nodes in
the resected specimen, and baseline CEAwere independently associated
with LR. Caution is required with interpretation because of the small
numberofeventsanalyzed;nevertheless,theresultsaffirmtheimportance
of resectionmargins, lymphnode involvement, andCEA level in LR.
We observed, as expected, that there was a greater pathologic T
and N downstaging effect with LC. However, there was no apparent
effect onAPRrate for distal tumors (79% v77%). Similarly, thePolish
trial did not find that long-course chemoradiotherapy reduced APR
rate.15 Itmaybe that downsizingwasnot sufficient to alter the surgical
approach, or there was concern about residual microscopic disease
even after a good response, or surgeons made their clinical decision
based on the pretherapy distal margin rather than perioperative clin-
ical response to radiotherapy. SC with early surgery does not allow
enough time for the tumor to regress, and so a reduction in APR rate
would not be expected. The effect of delayed surgery for SC will be
addressed by the Stockholm III trial.17
There is still some concern that late toxicity from hypofrac-
tionated SC radiotherapymay exceed that for fully fractionated LC.
We observed no significant difference in severe late toxicity at 3
years and, in particular, no reports of severe neuropathy.18 Longer
follow-up is required to fully assess late effects. Analysis of quality
of life data is planned to be performed after 5 years. Longer
follow-up is also being planned for local recurrence, as well as
distant recurrence and survival.
The trial data indicate that LCmay be more effective than SC in
reducing the risk of LR, especially for distal tumors.However,wehave
not been able to definitively determine that such a difference does
exist, and further study would be required to help clarify this issue. At
this stageof study, itmaybe reasonable to suggest apolicy thatdistal or
bulky tumors be treated with LC, and that where convenience is an
important consideration SC be used.
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